<DOC>
	<DOC>NCT00023361</DOC>
	<brief_summary>Primary objective: To determine the rate of confirmed treatment failure and relapse with an intermittent rifabutin-based regimen for the treatment of isoniazid and rifamycin-susceptible HIV-related tuberculosis (TB).</brief_summary>
	<brief_title>TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>Inclusion Criteria Clinical diagnosis of pulmonary &amp;/or extrapulmonary TB confirmed by a positive culture and susceptibility to rifampin. Patients having isoniazid or pyrazinamide (PZA)resistant isolates are eligible to continue in the study on a modified regimen Evidence of HIV infection confirmed by a positive serologic test (ELISA and Western Blot). Absolute neutrophil count &gt;500/mm3 (use of colony stimulating factors, filgrastim, or sargramostim is allowed) &gt; 18 years of age Willingness to practice effective contraception if applicable Signed informed consent Exclusion Criteria Pregnancy or breastfeeding AST &gt; 10 times the upper limit of normal Bilirubin &gt; 3.0 times the upper limit of normal Creatinine &gt; 3.0 times the upper limit of normal Intolerance to any of the study drugs except isoniazid or pyrazinamide Concomitant disorder that is contraindication to the use of the study drugs More than 28 days of treatment for active tuberculosis within the 6 months prior to this course of therapy Bone/joint tuberculosis or silicotuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>tuberculosis</keyword>
	<keyword>TB</keyword>
</DOC>